According to the new market research report "Protein Expression Market by
Type (E. Coli, Mammalian, Yeast, Pichia, Insect, Baculovirus, Cell-free),
Products (Competent Cells, Reagents, Instruments, Services), Application
(Therapeutic, Research, Industrial) & End User - Global Forecast to 2022 ",
published by MarketsandMarkets™, is expected to reach USD 2,850.5 Million by 2022 from USD
1,654.0 Million in 2017, at a CAGR of 11.5% during the forecast period.
The
prevalence of chronic diseases, increasing research activities on
recombinant-based proteins, and growing life sciences & biopharmaceutical
industries are the major factors driving the growth of this market.
Download PDF
Brochure:
By systems type,
the prokaryotic expression systems segment is expected to dominate the market
in 2017
On the basis of
systems type, the protein expression market is segmented into prokaryotic
expression systems; insect cell expression systems; mammalian cell expression
systems; yeast expression systems; cell-free expression systems; and
algal-based expression systems.
The prokaryotic
expression systems segment has been sub-segmented into Escherichia coli (E.
coli) systems and other systems. The E. coli systems segment accounted for the
largest share of this market segment. This growth can be attributed to the
increasing use of E. coli systems for the production of commercial proteins.
127 - Tables
38 - Figures
173 - Pages
By product, the
reagents segment is expected to hold the largest share of the market in 2017
The market is
segmented into competent cells, expression vectors, instruments, reagents, and
services on the basis of products. The reagents segment holds the largest share
and also expected to grow at the highest growth rate during the forecast
period. This positive growth trend is primarily attributed to increasing
research activities and large-scale production of antibodies and vaccines that
require kits and reagents.
The therapeutic
applications segment is expected to dominate the market in 2017
By application,
the market is segmented into therapeutic applications, research applications
and industrial applications.The therapeutic applications segment holds the
largest share in the market; however, the research applications segment is
expected to grow at the highest growth rate during the forecast period. Growth
in the research applications segment is primarily attributed to the increase in
proteomics-based research activities around the world.
By end user, the pharmaceutical
and biotechnology companies segment is expected to hold the largest share of
the market in 2017
On the basis of end users, the protein expression market is
segmented into academic research institutes; contract research organizations
(CROs); pharmaceutical and biotechnology companies; and other end users (food
processing industry, detergent manufacturers, paper industry, leather industry,
breweries, dairy industry, chemical industry, bioplastic industry, and
cosmeceutical industry).The pharmaceutical and biotechnology companies segment
holds the largest share in the market; however, the CROs segment is expected to
grow at the highest growth rate during the forecast period.
Asia offers lucrative growth
opportunities
By region, the global market is segmented into North America,
Europe, Asia, and the Rest of the World (RoW). While North America holds the
largest share of the market in 2016, Asia is expected to grow at the highest
CAGR during the forecast period. The presence of emerging economies like China
and India; the large population and rising prevalence of chronic diseases in
these countries; a growing demand of biologics; and the improving life sciences
research infrastructure are the major factors driving the growth of this
regional segment.
Key players operating in the protein expression market include
Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson
& Company (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V.
(Netherlands), Takara Bio Inc. (Japan), Lonza Group Ltd. (Switzerland), Bio-Rad
Laboratories, Inc. (U.S.), GenScript Biotech Corporation (China), Lucigen
Corporation (U.S.), Synthetic Genomics Inc. (U.S.)
